$NKTX News

Needham Reiterates Buy on Nkarta, Maintains $11 Price Target

Nkarta (NASDAQ:NKTX) Q1 2026 Narrower Loss Beats Estimates as Autoimmune Trial Advances

Nkarta Q1 EPS $(0.37), Inline

Nkarta shares are trading higher after the company announced an agreement with the FDA on protocols for its Ntrust-1 and Ntrust-2 clinical trials.

Nkarta shares are trading higher after the company announced an agreement with the FDA on protocols for its Ntrust-1 and Ntrust-2 clinical trials.

Nkarta Reveals FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease; Option To Redose Patients Granted In Both Ntrust-1 And Ntrust-2 Studies; Rheumatoid Arthritis Cohort To Be Added To Ntrust-2

Mizuho Maintains Outperform on Nkarta, Lowers Price Target to $12

Needham Maintains Buy on Nkarta, Raises Price Target to $11

Nkarta Files Base Prospectus To Offer Up To $350M In Securities

Nkarta Q4 EPS $(0.37) Misses $(0.34) Estimate

We Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth Carefully

Nkarta to Participate in Evercore Healthcare Conference

Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason

Stifel Maintains Buy on Nkarta, Lowers Price Target to $11

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nkarta Q3 EPS $(0.29) Beats $(0.35) Estimate

Nkarta to Participate in November Investor Conferences

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

Nkarta To Present NKX019 Data At ACR Convergence 2025 Showing Immune Reset In Non-Hodgkin Lymphoma And Preclinical Efficacy In Vitro Autoimmune Disease Models

Nkarta to Participate in a September Investor Conference